Xgeva (denosumab), which has already been approved by the Food and Drug Administration (FDA) for the prevention fractures in men with advanced prostate cancer that has already migrated to the bone, has been rejected by the FDA to expand the use of the drug to delay the spread of tumors in men without metastases to [...]
Rarely discussed, but very much a potential problem for men with advanced prostate cancer are neurological complications resulting from prostate cancer metastasis. Neurological complications of metastatic prostate cancer require quick treatment to minimize impact on a man, so early recognition is important. Family physicians when faced with a man complaining of low back pain or [...]
One of the major causes of prostate cancer morbidity and mortality is bone metastases. Currently, when it comes to treating prostate cancer metastases we are very limited in effective therapies that actually prolong survival. Kirschenbaum A, etal (Departments of Urology and Medicine Division of Pulmonary Diseases Division of Endocrinology, Metabolism, and Bone Diseases, Mount Sinai [...]